- Home
- AIRS vs GOSS Comparison
AIRS vs GOSS Comparison
Compare AIRS & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- GOSS
- Stock Information
- Founded
- AIRS 2012
- GOSS 2015
- Country
- AIRS United States
- GOSS United States
- Employees
- AIRS N/A
- GOSS N/A
- Industry
- AIRS Medical/Nursing Services
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- GOSS Health Care
- Exchange
- AIRS Nasdaq
- GOSS Nasdaq
- Market Cap
- AIRS 166.3M
- GOSS 262.5M
- IPO Year
- AIRS 2021
- GOSS 2019
- Fundamental
- Price
- AIRS $5.25
- GOSS $1.25
- Analyst Decision
- AIRS Hold
- GOSS Strong Buy
- Analyst Count
- AIRS 3
- GOSS 3
- Target Price
- AIRS $3.75
- GOSS $7.33
- AVG Volume (30 Days)
- AIRS 788.4K
- GOSS 2.6M
- Earning Date
- AIRS 08-08-2025
- GOSS 08-11-2025
- Dividend Yield
- AIRS N/A
- GOSS N/A
- EPS Growth
- AIRS N/A
- GOSS N/A
- EPS
- AIRS N/A
- GOSS N/A
- Revenue
- AIRS $172,101,000.00
- GOSS $124,590,000.00
- Revenue This Year
- AIRS N/A
- GOSS N/A
- Revenue Next Year
- AIRS $4.90
- GOSS $91.14
- P/E Ratio
- AIRS N/A
- GOSS N/A
- Revenue Growth
- AIRS N/A
- GOSS N/A
- 52 Week Low
- AIRS $1.53
- GOSS $0.66
- 52 Week High
- AIRS $9.20
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- AIRS 64.29
- GOSS 49.48
- Support Level
- AIRS $4.70
- GOSS $1.20
- Resistance Level
- AIRS $5.40
- GOSS $1.33
- Average True Range (ATR)
- AIRS 0.42
- GOSS 0.10
- MACD
- AIRS -0.03
- GOSS -0.02
- Stochastic Oscillator
- AIRS 94.23
- GOSS 18.37
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.